Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11758054 | 0.79 | RAPGEF4 (0.39) | RAPGEF4ALDH1A1AHRTSHRHSD17B10 | |
| SCHEMBL11758059 | 0.79 | RAPGEF4 (0.39) | RAPGEF4ALDH1A1AHRTSHRHSD17B10 | |
| SCHEMBL1021835 | 0.74 | GABRA1 (0.37) | RAPGEF4ALDH1A1AHRTSHRHSD17B10 | |
| SCHEMBL11883854 | 0.74 | HTR3E (0.47) | RAPGEF4ALDH1A1TSHRHSD17B10CYP3A4 | |
| SCHEMBL11283538 | 0.71 | CYP3A4 (0.41) | RAPGEF4ALDH1A1AHRCYP3A4 | |
| SCHEMBL6680393 | 0.71 | RAPGEF4 (0.42) | RAPGEF4ALDH1A1AHRHTT | |
| SCHEMBL11283536 | 0.71 | CYP3A4 (0.41) | RAPGEF4ALDH1A1AHRCYP3A4 | |
| SCHEMBL6640138 | 0.70 | RAPGEF4 (0.33) | RAPGEF4AHR | |
| SCHEMBL1405460 | 0.70 | MEN1 (0.57) | RAPGEF4ALDH1A1AHRTSHRHSD17B10 | |
| SCHEMBL1405458 | 0.70 | MEN1 (0.57) | RAPGEF4ALDH1A1AHRTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | claimed |
| EP-1150982-B1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-alpha | CV THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6790958-B2 | ANTIPROLIFERATIVE AGENTS; FUNGICIDES | LUM ROBERT T (US) | 2004-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | RAPGEF4 2766/4885ALDH1A1 3492/4885AHR 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.